1
|
Giovanis P, Pianezze G, Vincenzi V, Manuppelli C, Boaretto M, Pastorelli D. Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib. Hepat Oncol 2017; 4:39-43. [PMID: 30191052 DOI: 10.2217/hep-2016-0011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Accepted: 07/12/2017] [Indexed: 02/06/2023] Open
Abstract
Aim We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP). Materials & methods CECs in advanced HCC patients receiving sorafenib were counted at baseline and every 4 weeks. Results Twenty four HCC patients were enrolled in the study. Median TTP was 3.2 months (1-6). Median baseline CEC levels were 67 cells/ml, with an increase of 169.8% after 4 weeks of treatment. Any time CEC levels in patients with a TTP lower than 4 months were higher, but not statistically significant, compared with those in patients with TTP more than 4 months. Conclusion Treatment with sorafenib changed CEC levels in HCC patients.
Collapse
Affiliation(s)
- Petros Giovanis
- Medical Oncology Unit, City Hospital of Feltre, Via Bagnols Sul Ceze 3, 32032, Ulss 1 Dolomiti, Feltre, Italy.,Medical Oncology Unit, City Hospital of Feltre, Via Bagnols Sul Ceze 3, 32032, Ulss 1 Dolomiti, Feltre, Italy
| | - Graziano Pianezze
- Research Lab, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy.,Research Lab, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy
| | - Valter Vincenzi
- Internal Medicine & Hepatology, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy.,Internal Medicine & Hepatology, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy
| | - Carla Manuppelli
- Internal Medicine & Hepatology, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy.,Internal Medicine & Hepatology, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy
| | - Massimo Boaretto
- Internal Medicine & Hepatology, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy.,Internal Medicine & Hepatology, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy
| | - Davide Pastorelli
- Medical Oncology Unit, City Hospital of Feltre, Via Bagnols Sul Ceze 3, 32032, Ulss 1 Dolomiti, Feltre, Italy.,Medical Oncology Unit, City Hospital of Feltre, Via Bagnols Sul Ceze 3, 32032, Ulss 1 Dolomiti, Feltre, Italy
| |
Collapse
|
2
|
Hoxha A, Calligaro A, Tonello M, Ramonda R, Carletto A, Paolazzi G, Bortolotti R, Del Ross T, Grava C, Boaretto M, Favaro M, Teghil V, Ruffatti A, Punzi L. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study. Joint Bone Spine 2015; 83:167-71. [PMID: 26750762 DOI: 10.1016/j.jbspin.2015.04.020] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Accepted: 04/15/2015] [Indexed: 01/18/2023]
Abstract
OBJECTIVES To evaluate the relevance of anti-adalimumab (anti-ADA) antibodies (Abs) and their relationship with clinical/laboratory features in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). METHODS Fifty-eight patients affected with RA, AS and PsA were prospectively enrolled. Clinical/laboratory characteristics, disease activity, anti-ADA, anti-nuclear (ANA), anti-double strand (ds)DNA, anti-extractable nuclear antigens (anti-ENA) and anti-phospholipid Abs (aPL) were evaluated at baseline, 4, 12 and 24 weeks of adalimumab treatment. RESULTS Anti-ADA Abs were observed in 11/58 (19%) patients; they were detected within the 4th week of therapy in 90.9% of the positive subjects. Anti-ADA positivity was associated with significantly lower mean adalimumab serum levels (P<0.05). Treatment failure was observed in 20/58 (34.5%) patients and was significantly associated with anti-ADA Abs (P<0.05). Mean adalimumab serum levels were significantly lower in patients with treatment failure than in the responders one, both in the whole cohort (P<0.01) and in the group of anti-ADA positive patients (P<0.01). Adverse events happened more often in anti-ADA positive then in anti-ADA negative patients (27.3% vs 14.9%). CONCLUSIONS Anti-ADA abs could be considered an early marker associated to a poor clinical response to adalimumab treatment. Routine ANA/anti-ENA/aPL monitoring did not reveal as useful tools to predict the development of anti-ADA abs.
Collapse
Affiliation(s)
- Ariela Hoxha
- Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2-35128 Padova, Italy.
| | - Antonia Calligaro
- Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2-35128 Padova, Italy
| | - Marta Tonello
- Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2-35128 Padova, Italy
| | - Roberta Ramonda
- Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2-35128 Padova, Italy
| | - Antonio Carletto
- Rheumatology Unit, Department of Medicine, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy
| | - Giuseppe Paolazzi
- Rheumatology Unit, S. Chiara Hospital, Largo Medaglie D'oro, 9, 38122 Trento, Italy
| | - Roberto Bortolotti
- Rheumatology Unit, S. Chiara Hospital, Largo Medaglie D'oro, 9, 38122 Trento, Italy
| | - Teresa Del Ross
- Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2-35128 Padova, Italy
| | - Chiara Grava
- Department of Medicine, S. Martino Hospital, Viale Europa, 22, 32100 Belluno, Italy
| | - Massimo Boaretto
- Department of Medicine, S. Martino Hospital, Viale Europa, 22, 32100 Belluno, Italy
| | - Maria Favaro
- Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2-35128 Padova, Italy
| | - Vera Teghil
- Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2-35128 Padova, Italy
| | - Amelia Ruffatti
- Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2-35128 Padova, Italy
| | - Leonardo Punzi
- Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2-35128 Padova, Italy
| |
Collapse
|
3
|
Hoxha A, Calligaro A, Tonello M, Carletto A, Paolazzi G, Bortolotti R, Felicetti M, Ramonda R, Del Ross T, Grava C, Boaretto M, Favaro M, Teghil V, Ruffatti A, Punzi L. AB0371 Clinical Significance of Anti-Adalimumab Antibodies in Rheumatoid Arthritis, Ankylosing Spondilitis and Psoriasic Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5938] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
4
|
Nardelli E, Agazzi P, Polo A, Boaretto M, Cavallaro T, Ferracci F, Moretto G, Rizzuto N. HYPERTROPHY OF SPINAL ROOTS IN CHRONIC INFLAMMATORY DEMYELINATING NEUROPATHY. J Peripher Nerv Syst 2000. [DOI: 10.1046/j.1529-8027.2000.00513-41.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- E. Nardelli
- Department of Neurological and Visual Sciences, Section of Clinical Neurology, University of Verona, Verona, Italy. Departments of Medicine Neurology and of
| | - P. Agazzi
- Department of Neurological and Visual Sciences, Section of Clinical Neurology, University of Verona, Verona, Italy. Departments of Medicine Neurology and of
| | - A. Polo
- Department of Neurological and Visual Sciences, Section of Clinical Neurology, University of Verona, Verona, Italy. Departments of Medicine Neurology and of
| | - M. Boaretto
- Department of Neurological and Visual Sciences, Section of Clinical Neurology, University of Verona, Verona, Italy. Departments of Medicine Neurology and of
| | - T. Cavallaro
- Department of Neurological and Visual Sciences, Section of Clinical Neurology, University of Verona, Verona, Italy. Departments of Medicine Neurology and of
| | | | | | - N Rizzuto
- Ospedale di Belluno, , Belluno, Italy
| |
Collapse
|